CNSP
CNS Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.99
+2.87%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -8.0%
- EBIT
- -8.6%
- EPS
- +88.4%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +93.5%
Three-year CAGR
- Revenue
- —
- EBITDA
- -6.7%
- EBIT
- -7.3%
- Net income
- -6.7%
- EPS
- +92.3%
- Free cash flow
- +19.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026